Latest Pharma Insights
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Zealand CEO calls for end to 'weight loss Olympics'; MSD on AI-assisted pipelines; Bruce Levine’s CAR-T stories; biopharma dealmaking bounces back; and 2025 was a tough year for US IPOs.
Scrip - March 2, 2026
In this week's episode: Zealand CEO calls for end to 'weight loss Olympics'; MSD on AI-assisted pipelines; Bruce Levine’s CAR-T stories; biopharma dealmaking bounces back; and 2025 was a tough year for US IPOs.
Scrip - March 2, 2026
What Does Big Pharma Want From CRDMOs As AI Changes Rules?
CRDMOs must embrace AI to keep pace with big pharma partners - but what is expected of them, which data can they use, where are Indian firms on the adoption curve and does the ‘China Plus One’ business proposition still hold? Leaders discussed these topics at BioAsia.
Scrip - March 2, 2026
CRDMOs must embrace AI to keep pace with big pharma partners - but what is expected of them, which data can they use, where are Indian firms on the adoption curve and does the ‘China Plus One’ business proposition still hold? Leaders discussed these topics at BioAsia.
Scrip - March 2, 2026
US FDA Commits In PDUFA Meetings To Help OTC Industry On Special Protocols, Stepwise Labeling
Including OTC studies in special protocol assessments will be addressed in FDA guidance required in 15 months on improving predictability of process and standards for approval of OTC drug applications, while stepwise labeling information will be post online to improve visibility and searchability fo
HBW Insight - March 2, 2026
Including OTC studies in special protocol assessments will be addressed in FDA guidance required in 15 months on improving predictability of process and standards for approval of OTC drug applications, while stepwise labeling information will be post online to improve visibility and searchability fo
HBW Insight - March 2, 2026
J&J Focuses On Weeding Out ‘Junk Science’ As Debate Over Talc Experts Continues
After its attempt to resolve tens of thousands of talc lawsuits through bankruptcy court failed, Johnson & Johnson is working to exclude what it sees as scientifically dubious testimony from cases.
HBW Insight - March 2, 2026
After its attempt to resolve tens of thousands of talc lawsuits through bankruptcy court failed, Johnson & Johnson is working to exclude what it sees as scientifically dubious testimony from cases.
HBW Insight - March 2, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Zealand CEO calls for end to 'weight loss Olympics'; MSD on AI-assisted pipelines; Bruce Levine’s CAR-T stories; biopharma dealmaking bounces back; and 2025 was a tough year for US IPOs.
Scrip - March 2, 2026
In this week's episode: Zealand CEO calls for end to 'weight loss Olympics'; MSD on AI-assisted pipelines; Bruce Levine’s CAR-T stories; biopharma dealmaking bounces back; and 2025 was a tough year for US IPOs.
Scrip - March 2, 2026
What Does Big Pharma Want From CRDMOs As AI Changes Rules?
CRDMOs must embrace AI to keep pace with big pharma partners - but what is expected of them, which data can they use, where are Indian firms on the adoption curve and does the ‘China Plus One’ business proposition still hold? Leaders discussed these topics at BioAsia.
Scrip - March 2, 2026
CRDMOs must embrace AI to keep pace with big pharma partners - but what is expected of them, which data can they use, where are Indian firms on the adoption curve and does the ‘China Plus One’ business proposition still hold? Leaders discussed these topics at BioAsia.
Scrip - March 2, 2026
After CMS Coverage, Superficial Radiotherapy Firm Eyes Bigger Role In Skin Cancer Treatment
The US Medicare agency is now covering superficial radiotherapy (SRT) for the treatment of skin cancer. Joseph Sardano, CEO of SRT firm Sensus Healthcare, spoke to Medtech Insight about the potential of the technology and why it’s still facing adaptation challenges.
Medtech Insight - February 27, 2026
The US Medicare agency is now covering superficial radiotherapy (SRT) for the treatment of skin cancer. Joseph Sardano, CEO of SRT firm Sensus Healthcare, spoke to Medtech Insight about the potential of the technology and why it’s still facing adaptation challenges.
Medtech Insight - February 27, 2026
Digital Health Roundup: BCI, Neuroethics, FDA Shifts, Wearables, And Megadeals
As brain-computer interfaces near US approval, neuroethics and neural data privacy move center stage. Major medtech deals reshape the market, while new FDA digital health leadership and updated AI, wellness and CDS guidances signal a more flexible regulatory approach.
Medtech Insight - February 27, 2026
As brain-computer interfaces near US approval, neuroethics and neural data privacy move center stage. Major medtech deals reshape the market, while new FDA digital health leadership and updated AI, wellness and CDS guidances signal a more flexible regulatory approach.
Medtech Insight - February 27, 2026
Serious Injuries Linked To Abiomed Impella Heart Pump Component
The US FDA has issued an early alert concerning Abiomed’s Impella purge cassettes, a critical heart pump component that delivers rinsing fluid to the Impella catheter.
Medtech Insight - February 27, 2026
The US FDA has issued an early alert concerning Abiomed’s Impella purge cassettes, a critical heart pump component that delivers rinsing fluid to the Impella catheter.
Medtech Insight - February 27, 2026
One Call Point, One Vision: Precision CEO Kurt Azarbazin’s Plan To Redefine Interventional Oncology
New Precision IO Group CEO Kurt Azarbarzin outlines the near-term strategy for Quantum Surgical’s robotic-assisted ablation platform and NeuWave Medical’s microwave technology. Quantum recently acquired NeuWave, but the companies will continue to operate independently.
Medtech Insight - February 27, 2026
New Precision IO Group CEO Kurt Azarbarzin outlines the near-term strategy for Quantum Surgical’s robotic-assisted ablation platform and NeuWave Medical’s microwave technology. Quantum recently acquired NeuWave, but the companies will continue to operate independently.
Medtech Insight - February 27, 2026
US FDA Commits In PDUFA Meetings To Help OTC Industry On Special Protocols, Stepwise Labeling
Including OTC studies in special protocol assessments will be addressed in FDA guidance required in 15 months on improving predictability of process and standards for approval of OTC drug applications, while stepwise labeling information will be post online to improve visibility and searchability fo
HBW Insight - March 2, 2026
Including OTC studies in special protocol assessments will be addressed in FDA guidance required in 15 months on improving predictability of process and standards for approval of OTC drug applications, while stepwise labeling information will be post online to improve visibility and searchability fo
HBW Insight - March 2, 2026
J&J Focuses On Weeding Out ‘Junk Science’ As Debate Over Talc Experts Continues
After its attempt to resolve tens of thousands of talc lawsuits through bankruptcy court failed, Johnson & Johnson is working to exclude what it sees as scientifically dubious testimony from cases.
HBW Insight - March 2, 2026
After its attempt to resolve tens of thousands of talc lawsuits through bankruptcy court failed, Johnson & Johnson is working to exclude what it sees as scientifically dubious testimony from cases.
HBW Insight - March 2, 2026
What’s Next? Five Things To Look Out For In March 2026
Generics Bulletin previews the most noteworthy and anticipated events for March 2026.
Generics Bulletin - March 1, 2026
Generics Bulletin previews the most noteworthy and anticipated events for March 2026.
Generics Bulletin - March 1, 2026
Podcast: Affibody And The Case For Antibody Mimetics In Radioligand Therapy
Swedish biotech Affibody is using tiny engineered proteins to expand radioligand therapy's target space. CEO David Bejker details its HER2 program, Albumod technology and partnership strategy.
In Vivo - February 26, 2026
Swedish biotech Affibody is using tiny engineered proteins to expand radioligand therapy's target space. CEO David Bejker details its HER2 program, Albumod technology and partnership strategy.
In Vivo - February 26, 2026
How Asia’s Biopharma Transformation Is Reshaping Global Deal Flow
A decade ago, China was buying Western drugs. Now it is selling them. Executives who ignore the shift do so at their peril.
In Vivo - February 26, 2026
A decade ago, China was buying Western drugs. Now it is selling them. Executives who ignore the shift do so at their peril.
In Vivo - February 26, 2026